Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lowered its position in Arcus Biosciences, Inc. (NYSE:RCUS) by 6.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 42,360 shares of the company’s stock after selling 2,943 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Arcus Biosciences were worth $648,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in RCUS. Louisiana State Employees Retirement System raised its stake in shares of Arcus Biosciences by 2.6% in the 2nd quarter. Louisiana State Employees Retirement System now owns 27,500 shares of the company’s stock valued at $419,000 after purchasing an additional 700 shares in the last quarter. Diversified Trust Co raised its stake in shares of Arcus Biosciences by 12.1% in the 2nd quarter. Diversified Trust Co now owns 13,545 shares of the company’s stock valued at $206,000 after purchasing an additional 1,467 shares in the last quarter. WINTON GROUP Ltd raised its stake in shares of Arcus Biosciences by 3.3% in the 2nd quarter. WINTON GROUP Ltd now owns 59,137 shares of the company’s stock valued at $901,000 after purchasing an additional 1,872 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Arcus Biosciences by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 34,764 shares of the company’s stock valued at $657,000 after purchasing an additional 1,906 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Arcus Biosciences by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 58,173 shares of the company’s stock valued at $886,000 after purchasing an additional 1,951 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Barclays increased their price objective on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. HC Wainwright reiterated a “neutral” rating and set a $20.00 price objective on shares of Arcus Biosciences in a research note on Wednesday, November 6th. Wells Fargo & Company initiated coverage on shares of Arcus Biosciences in a research note on Tuesday, October 8th. They set an “overweight” rating and a $29.00 price objective on the stock. Finally, Evercore ISI upgraded shares of Arcus Biosciences to a “strong-buy” rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $34.00.

Arcus Biosciences Stock Up 4.0 %

RCUS stock opened at $17.10 on Thursday. Arcus Biosciences, Inc. has a 12 month low of $13.52 and a 12 month high of $20.31. The firm has a market cap of $1.56 billion, a PE ratio of -5.43 and a beta of 0.88. The firm has a 50 day simple moving average of $16.27 and a 200 day simple moving average of $16.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.06. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The business had revenue of $48.00 million during the quarter, compared to analyst estimates of $38.95 million. During the same period in the prior year, the business earned ($0.94) earnings per share. The business’s quarterly revenue was up 50.0% on a year-over-year basis. Equities research analysts forecast that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current fiscal year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.